Tarek Taha (@tarektahamd) 's Twitter Profile
Tarek Taha

@tarektahamd

Medical #Oncologist at @rambamhcc. Save Earth, Its the only planet with chocolate.

ID: 194549921

linkhttps://www.linkedin.com/in/tarek-taha-89a886188 calendar_today24-09-2010 12:16:39

14 Tweet

28 Followers

117 Following

Tarek Taha (@tarektahamd) 's Twitter Profile Photo

Everolimus (mTor inh) like most TKIs, fail to significantly improve RFS/DFS in RCC adjuvant setting. Hope ICIs will show OS improvement in the near future. #ASCO22 #KCSM #EVEREST

Tarek Taha (@tarektahamd) 's Twitter Profile Photo

#CBM588 decreases antibiotic resistance genes resulting in better response to ICIs. Another move forward in tailoring #cancer treatment. #ASCO22 #KCSM

Tarek Taha (@tarektahamd) 's Twitter Profile Photo

Neoadjuvant dostarlimab (anti PD-1) resulted in 100% clinical CR in 12 patients with MMRd stage II/III Rectal cancer. Small cohort and relatively short follow up, yet looks promising 👌🏽. #ASCO22 #CRCSM

Tarek Taha (@tarektahamd) 's Twitter Profile Photo

Wrapping up #ASCO22, here’s my starting 5 across all tracks: Tdx in HER2-low mBC, Dostarlimab in Rectal ca, ctDNA in Adj CRC and HER2- breast, Lu-177 in mCRPC, ADCs incorporated almost in all fields. Revolution is alive. #Destiny #Breast04 #DYNAMIC #CHiRP #VISION #TheraP #ADC

Tarek Taha (@tarektahamd) 's Twitter Profile Photo

Collaborative efforts are necessary to improve MENA representation in future oncology research. #MENA #ClinicalTrials #Oncology

EORTC (@eortc) 's Twitter Profile Photo

#MCCRWorkshop Faculty & Fellows, class of 2025! Since 1999, this workshop has fostered innovation, collaboration, and groundbreaking research in clinical cancer. #EORTC ESMO - Eur. Oncology AACR

#MCCRWorkshop Faculty & Fellows, class of 2025! Since 1999, this workshop has fostered innovation, collaboration, and groundbreaking research in clinical cancer. 

#EORTC <a href="/myESMO/">ESMO - Eur. Oncology</a> <a href="/AACR/">AACR</a>
Mirrors of Medicine (@mirrorsmed) 's Twitter Profile Photo

Immune-based Combinations in Intermediate-/Poor-risk Patients with Non–clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study sciencedirect.com/science/articl… This multicenter, retrospective study evaluated the real-world efficacy of first-line immune-based combinations in 323

Immune-based Combinations in Intermediate-/Poor-risk Patients with Non–clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study 

sciencedirect.com/science/articl…

This multicenter, retrospective study evaluated the real-world efficacy of first-line immune-based combinations in 323